Aceragen Inc expected to post a loss of $2.12 a share - Earnings Preview

Aceragen

13/05/2023 03:05

* Aceragen Inc  ACGN.OQ   ACGN.O  is expected to show no
change in
quarterly revenue when it reports  results on May 12
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Aceragen Inc is for
a
loss of $2.12 per share. 
    * The one available analyst rating on the shares is "buy".  
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "Buy".​
    * Wall Street's median 12-month price target for Aceragen
Inc is
$17​, above​ its last closing price of $1.50. ​​​

This summary was machine generated May 13 at 02:05 GMT.  All
figures in US dollars  unless otherwise stated